Summary
53 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: ¥51.0B against ¥24.2B.
- It has been profitable 6 years in a row.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 15% a year over the last 3 years.
- It earns only 5.7 JPY a year on every 100 JPY of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 38.5 JPY for 1 JPY of yearly profit. Over the last five years it was 33.8 JPY on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 4.0% a year over 5 years. Over the last 3 years it grew by 3.2% a year. Earnings per share fell by 15% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 JPY of revenue goes
- Cost of sales 48 JPY
- Research and development 3.3 JPY
- Sales and administration 42 JPY
- Taxes and other 1.2 JPY
- Net profit 5.8 JPY
Net profit, industry median (Medical - Devices) 6.5 JPY
Out of every 100 JPY of revenue, 5.8 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.4 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 1.76%
- Paid out of profit
- 68%
- Raised in a row
- 1 year
You receive $0.18 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.